Current Gastroenterology Reports

, Volume 7, Issue 6, pp 485–491

Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis

  • Laurence J. Egan
  • William J. Sandborn
Article

DOI: 10.1007/s11894-005-0080-3

Cite this article as:
Egan, L.J. & Sandborn, W.J. Curr Gastroenterol Rep (2005) 7: 485. doi:10.1007/s11894-005-0080-3

Abstract

Traditional medications for inflammatory bowel disease are small molecule drugs, most of which were developed for use in other diseases before being found to be efficacious for the treatment of ulcerative colitis or Crohn’s disease. Recently, several exciting alternative approaches to the medical treatment of inflammatory bowel disease have been developed. These include biologic, probiotic, and apheresis therapies that offer certain advantages over traditional drug therapy for inflammatory bowel disease. The purpose of this review is to assess the current state of knowledge about novel biologic, probiotic, and apheresis therapies and to analyze how best to incorporate these therapies into evolving management paradigms of inflammatory bowel disease.

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Laurence J. Egan
    • 1
  • William J. Sandborn
  1. 1.Department of PharmacologyNational University of Ireland, Clinical Science Institute, University College HospitalGalwayIreland

Personalised recommendations